NCT05677659: An ongoing trial by Vigil Neuroscience, Inc.
This trial is ongoing. It must report results 2 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05677659 |
|---|---|
| Title | A Phase 2 Safety, Tolerability, and Proof-of-Concept Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia (ALSP) (The Ignite Study) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 14, 2022 |
| Completion date | Feb. 14, 2025 |
| Required reporting date | Feb. 14, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |